Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX 130 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT-LYM
  • Sponsors CRISPR Therapeutics

    • Most Recent Events

    • 20 Mar 2024 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2022 According to a CRISPR Therapeutics media release, the company The Company continues to enroll and dose patients in the dose expansion part of the trial.
    • 17 Jun 2022 Results (n=15; As of 6 Dec, 2021) assessing safety and efficacy of CTX130 in with relapsed/refractory T-cell malignancies, presented at the 27th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top